SARS-CoV-2 virulence evolution: Avirulence theory, immunity and trade-offs.

epidemiology genomics immune escape immunopathology maladaptation trade-off virus

Journal

Journal of evolutionary biology
ISSN: 1420-9101
Titre abrégé: J Evol Biol
Pays: Switzerland
ID NLM: 8809954

Informations de publication

Date de publication:
12 2021
Historique:
revised: 15 06 2021
received: 09 04 2021
accepted: 21 06 2021
pubmed: 2 7 2021
medline: 31 12 2021
entrez: 1 7 2021
Statut: ppublish

Résumé

The COVID-19 pandemic has led to a resurgence of the debate on whether host-parasite interactions should evolve towards avirulence. In this review, we first show that SARS-CoV-2 virulence is evolving, before explaining why some expect the mortality caused by the epidemic to converge towards that of human seasonal alphacoronaviruses. Leaning on existing theory, we then include viral evolution into the picture and discuss hypotheses explaining why the virulence has increased since the beginning of the pandemic. Finally, we mention some potential scenarios for the future.

Identifiants

pubmed: 34196431
doi: 10.1111/jeb.13896
pmc: PMC8447366
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1867-1877

Informations de copyright

© 2021 European Society for Evolutionary Biology.

Références

Trends Microbiol. 1994 Mar;2(3):73-6
pubmed: 8156274
Science. 2021 Apr 16;372(6539):
pubmed: 33688063
J Infect. 2022 Jan;84(1):94-118
pubmed: 34329672
Science. 2014 Mar 21;343(6177):1243727
pubmed: 24653038
BMC Infect Dis. 2021 Mar 11;21(1):257
pubmed: 33706702
J Evol Biol. 2009 Feb;22(2):245-59
pubmed: 19196383
BMJ Open. 2020 Aug 16;10(8):e039652
pubmed: 32801208
Infect Genet Evol. 2020 Sep;83:104351
pubmed: 32387564
Clin Microbiol Rev. 1988 Jan;1(1):40-53
pubmed: 3060244
J Evol Biol. 2018 Jul;31(7):995-1005
pubmed: 29668109
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283
pubmed: 33589829
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Science. 2020 Oct 30;370(6516):564-570
pubmed: 32912998
Am Nat. 2004 Apr;163(4):E40-63
pubmed: 15122509
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Mod Pathol. 2020 Nov;33(11):2128-2138
pubmed: 32572155
JAMA. 2021 Apr 6;325(13):1324-1326
pubmed: 33571356
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
PLoS Pathog. 2021 Apr 8;17(4):e1009453
pubmed: 33831132
Nat Rev Genet. 2021 Jul;22(7):415-426
pubmed: 33948037
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Trends Ecol Evol. 2018 Jun;33(6):458-473
pubmed: 29665966
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Lancet Infect Dis. 2021 May;21(5):629-636
pubmed: 33545090
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Am Nat. 2010 May;175(5):E105-18
pubmed: 20297955
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6146-51
pubmed: 15071187
Trends Ecol Evol. 2008 Apr;23(4):188-93
pubmed: 18295930
BMC Med. 2021 Apr 27;19(1):106
pubmed: 33902581
Am Nat. 2008 Sep;172(3):E113-21
pubmed: 18710338
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Trends Ecol Evol. 2015 May;30(5):248-54
pubmed: 25837917
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Trends Immunol. 2020 Dec;41(12):1100-1115
pubmed: 33132005
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922
Hist Philos Life Sci. 2012;34(4):561-601
pubmed: 23607167
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
PLoS Biol. 2020 Nov 9;18(11):e3001000
pubmed: 33166303
medRxiv. 2021 Jul 25;:
pubmed: 33688681
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23652-23662
pubmed: 32868447
Proc Natl Acad Sci U S A. 2020 May 26;117(21):11541-11550
pubmed: 32385153
N Engl J Med. 2021 May 13;384(19):1866-1868
pubmed: 33761203
Nature. 2001 Dec 13;414(6865):751-6
pubmed: 11742400
Clin Microbiol Infect. 2022 Feb;28(2):298.e9-298.e15
pubmed: 34627988
Bioinformatics. 2018 Dec 1;34(23):4121-4123
pubmed: 29790939
Lancet Infect Dis. 2020 Dec;20(12):1381-1389
pubmed: 32822577
Proc Biol Sci. 1998 Feb 22;265(1393):317-25
pubmed: 9523434
medRxiv. 2021 Mar 03;:
pubmed: 33688664
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Cell. 2020 Sep 3;182(5):1295-1310.e20
pubmed: 32841599
Nat Commun. 2020 Nov 25;11(1):5986
pubmed: 33239633
Nature. 2021 May;593(7858):270-274
pubmed: 33723411
Nat Microbiol. 2020 Nov;5(11):1408-1417
pubmed: 32724171
J Evol Biol. 2021 Dec;34(12):1867-1877
pubmed: 34196431
Nat Microbiol. 2020 Apr;5(4):536-544
pubmed: 32123347
Emerg Infect Dis. 2021 May;27(5):1496-1499
pubmed: 33769253
PLoS Pathog. 2013 Mar;9(3):e1003209
pubmed: 23516359
Parasitology. 1982 Oct;85 (Pt 2):411-26
pubmed: 6755367
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Theor Biol. 2017 Apr 21;419:278-289
pubmed: 28193485
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Ecol Lett. 2013 Apr;16(4):556-67
pubmed: 23347009
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Am J Epidemiol. 2016 Apr 1;183(7):657-63
pubmed: 26851269
Science. 2021 Feb 12;371(6530):741-745
pubmed: 33436525
Proc Biol Sci. 2009 Jun 22;276(1665):2217-26
pubmed: 19324776
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284
Curr Biol. 2020 Aug 3;30(15):R849-R857
pubmed: 32750338
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
J Theor Biol. 1983 Feb 7;100(3):411-26
pubmed: 6834864
Trends Microbiol. 2017 Jan;25(1):35-48
pubmed: 27743750
Nat Microbiol. 2020 Nov;5(11):1403-1407
pubmed: 32669681
Science. 1998 Nov 20;282(5393):1432-5
pubmed: 9822369
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773

Auteurs

Samuel Alizon (S)

MIVEGEC, CNRS, IRD, Univ. Montpellier, Montpellier, France.

Mircea T Sofonea (MT)

MIVEGEC, CNRS, IRD, Univ. Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH